巴西混合人群HIV队列中依非韦伦药代动力学的药物遗传学预测因素
在82例稳定接受含600 mg依非韦伦方案治疗的巴西HIV成人中,依非韦伦血浆浓度及代谢比存在50倍个体间差异;CYP2B6代谢表型或rs3745274与rs28399499组合基因型是依非韦伦暴露与代谢比的显著预测因素,可解释血药浓度变异的48%和代谢比变异的35%。
要点
- 依非韦伦血药浓度个体间差异达50倍,CYP2B6基因型可解释48%的浓度变异。
- 69.5%患者血药浓度在名义治疗范围1000–4000 ng/mL内,19.5%低于下限,11.0%高于上限。
- 约1/10患者血药浓度超过4000 ng/mL但耐受良好,1/5低于1000 ng/mL但病毒学应答充分。
核心结论
- CYP2B6代谢表型或rs3745274与rs28399499组合基因型是依非韦伦血药浓度和8-OH-EFV/EFV代谢比的显著预测因素。
- 稳定接受含依非韦伦方案治疗的巴西HIV患者中,依非韦伦暴露和处置存在广泛个体间变异。
研究设计与样本
- 在2所大学医院招募82例稳定接受含600 mg依非韦伦每日一次方案至少6个月的HIV阳性成人。
- 于给药间隔中点采血,测定依非韦伦血浆浓度、主要代谢物8-OH-EFV浓度及代谢比,并检测CYP2B6 rs3745274、rs28399499和ABCB1 rs3842基因多态性。
- 采用线性回归模型识别依非韦伦浓度和代谢比的 sociodemographic、临床及药物遗传学预测因素。
主要发现
- 依非韦伦浓度、8-OH-EFV浓度及8-OH-EFV/EFV代谢比均呈现50倍个体间变异。
- 69.5%参与者依非韦伦浓度在名义治疗范围1000–4000 ng/mL内,19.5%低于1000 ng/mL,11.0%高于4000 ng/mL。
- 多因素回归仅保留CYP2B6代谢表型或rs3745274与rs28399499组合基因型作为依非韦伦浓度和代谢比的显著预测因素。
- CYP2B6两个单核苷酸多态性基因型解释依非韦伦浓度变异的48%和代谢比变异的35%。
关键数值与推荐
- 依非韦伦名义治疗范围为1000–4000 ng/mL;低于1000 ng/mL为名义亚治疗浓度,高于4000 ng/mL为名义超治疗浓度。
- CYP2B6代谢表型由CYP2B6双倍型推断。
临床怎么用
- 对于接受含依非韦伦方案治疗的HIV患者,可考虑CYP2B6基因型(rs3745274和rs28399499)辅助预测依非韦伦暴露水平。
- 依非韦伦浓度低于1000 ng/mL者仍可能获得充分病毒学应答,高于4000 ng/mL者也可能耐受良好,解读浓度时需结合临床应答。
局限性
- 样本量82例,来自2所大学医院,结果外推需谨慎。
- 仅在给药间隔中点单次采血测浓度,未评估完整药时曲线。
- 未报告ABCB1 rs3842在最终模型中的效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To investigate the influence of pharmacogenetic polymorphisms on efavirenz (EFV) exposure and metabolism in HIV-infected Brazilians under treatment with EFV-containing antiretroviral (ART) regimens. METHODS: HIV-positive adults (n = 82) on stable ART regimens containing 600 mg EFV once daily for at least 6 months were recruited at 2 university hospitals. Blood samples collected at mid-dose interval were used to quantify the plasma concentrations of EFV (denoted [EFV]), its major metabolite 8-OH-EFV ([8-OH-EFV]) and [8-OH-EFV]/[EFV] metabolic ratio, and to genotype single nucleotide polymorphisms in CYP2B6 (rs3745274, c.516G > T; rs28399499, c.983 T > C) and ABCB1 (rs3842, c.4036G > A). CYP2B6 metabolic phenotypes were inferred from the CYP2B6 diplotypes. Linear regression modelling was applied to identify sociodemographic, clinical and pharmacogenetic predictors of [EFV] and [8-OH-EFV]/[EFV] metabolic ratio. RESULTS: Wide (50-fold) interindividual variation in [EFV], [8-OH-EFV] and [8-OH-EFV]/[EFV] was observed; 69.5% of participants had [EFV] within the nominal therapeutic range (1000-4000 ng/mL), while 19.5 and 11.0% had [EFV] below and above this range, respectively. Multiple regression modelling retained only CYP2B6 metabolic phenotypes or the combined rs3745274 and rs28399499 genotypes, as significant predictors of [EFV] and [8-OH-EFV]/[EFV]. CONCLUSION: EFV exposure and disposition varied widely among HIV-infected Brazilians under stable treatment with EFV-containing ART regimens. About 1/10 of the participants had [EFV] exceeding nominal supratherapeutic concentration (4000 ng/mL), but reported tolerance to the ARV regimens, while 1/5 of participants had nominal subtherapeutic [EFV] (<1000 ng/mL) but adequate virological response. Genotype for the 2 CYP2B6 single nucleotide polymorphisms studied explained 48% of variation in [EFV] and 35% of variation in [8-OH-EFV]/[EFV].
引用
- Ximenez JP, Elias ABR, Nardotto GHB, et al. Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort. Br J Clin Pharmacol. 2022. PMID: 35514050. doi:10.1111/bcp.15387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。